Kyverna Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Operating income | -$169.8 | -$142.6 | -$62.4 | — |
| Net income | -$161.3 | -$127.5 | -$60.4 | — |
| Cash Flow Statement | ||||
| Free cash flow | -$153.7 | -$116.5 | -$53.0 | — |
Shares outstanding 61.8M · Free float 50.2%
Annual filing data through FY ended December 31, 2025; float as of October 6, 2026.